MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Tekmira Pharmaceuticals (TKMR) Obtains FDA Approval to Initiate TKM-Ebola Phase I Clinical Trial 0 comments
    Nov 28, 2011 3:00 PM | about stocks: ABUS

    Located in Vancouver, British Columbia, Tekmira is focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Today, Tekmira took a major step towards prominence with the announcement that its Investigational New Drug (NYSE:IND) application for TKM-Ebola has been approved by the United States Food and Drug Administration (FDA) allowing Tekmira to initiate a Phase 1 clinical trial.

    Tekmira is developing TKM-Ebola, a systemically delivered RNAi therapeutic that utilizes Tekmira’s lipid nanoparticle (LNP) delivery technology for the treatment of Ebola virus infection. Currently, there are no approved treatments for Ebola or other hemorrhagic fever viruses. With this approval, Tekmira has an opportunity to become a pioneer within the sector.

    Leading the way at Tekmira is Dr. Mark J. Murray whom serves as the company’s President and CEO. In reference to this press release, Dr. Murray stated, “We are pleased to have received the FDA’s approval of our TKM-Ebola IND. With this approval, we remain on track to achieve another significant milestone for the company by initiating the Phase 1 clinical trial of this product in early 2012.” Dr. Murray further added, “TKM-Ebola is being developed under a $140 million contract awarded to us by the U.S. Government’s Transformational Medical Technologies (TMT) Program. We look forward to continuing this successful collaboration to drive the TKM-Ebola program forward in clinical development.”

    Currently, Tekmira is trading in the in the $1.45 range. To learn more about this press release or the company as a whole, visit the company’s corporate website at www.tekmirapharm.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: ABUS
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.